List view / Grid view
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
In lab and mouse experiments researchers have developed a method to leverage B cells to manufacture and secrete tumour-suppressing microRNAs...
Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints,…
War On Cancer 2018 discussed how cancer treatments have evolved over the last few decades, and looked at the future of cancer therapies...
RIP1 has been shown to suppress the action of macrophages against the immune system and could be a potential therapeutic target for pancreatic cancer...
An experimental cancer vaccine that boosts the immune system's ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumours, scientists have reported...
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...
Genetic barcoding using Pro-codes and CRISPR could be used to identify critical cancer immunity genes to aid future therapeutics...
Immunotherapy using 'educated' killer cells could be a potential cure for pancreatic cancer, with researchers eliminating all signs of cancer from mice...
Researchers have identified camelid nanobodies that are able to block EGF, a protein that is abundant in tumour cells...
DNA vaccine optimised to cross-react with several MAGE-A isoforms generates a robust immune response and antitumour activity in a pre-clinical model of melanoma...
Cancer cells have been found to evade immunotherapy by hiding behind human leukocyte antigens, with researchers identifying therapies to prevent relapse...
Researchers in the U.S. have made a surprising discovery about the binding behaviour of a particular T-cell receptor, with complicated ramifications for immunotherapy developers.
Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…
Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.
